A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Novartis
Merck Sharp & Dohme LLC
Ipsen
DualityBio Inc.
Incyte Corporation
Thomas Jefferson University
Genentech, Inc.
UNICANCER
Jiangnan University
Arno Therapeutics